FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY
A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.
1 .- 20 . (canceled)
21 . A crystalline form of psilocin hydrobromide salt.
22 . The crystalline form of claim 21 , having an X-ray power diffraction pattern as depicted in FIG. 41 A .
23 . The crystalline form of claim 21 , having an endothermic event at about 145.6° C., as measured by differential scanning calorimetry from ambient temperature to 300° C. at a rate of 10° C. per minute.
24 . A pharmaceutical composition comprising the crystalline form of claim 21 and at least one agent that provides enhanced stability.
25 . The pharmaceutical composition of claim 24 , wherein the agent that provides enhanced stability is a photostabilizing agent or an antioxidant.
26 . A method of treating anxiety, comprising administering to a subject a crystalline form of psilocin hydrobromide salt.
27 . A method of treating depression, comprising administering to a crystalline form of psilocin hydrobromide salt.
28 . A method of treating anxiety, comprising administering to a subject the pharmaceutical composition of claim 24 .
29 . A method of treating depression, comprising administering to a subject the pharmaceutical composition of claim 24 .